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Abstract 31 
Vitamin D receptor (VDR) deficient status has been shown to be associated with the 32 
activation of renin angiotensin system (RAS).  We hypothesized that lack of VDR would 33 
enhance  p53 expression in podocytes through down regulation of SIRT1; the former 34 
would enhance the transcription of angiotensinogen (Agt) and angiotensinogen II type 1 35 
receptor (AT1R) leading to the activation of RAS. Renal tissues of VDR mutant (M) mice 36 
displayed increased expression of p53, Agt, renin, and AT1R. In vitro studies, VDR 37 
knockout podocytes not only displayed up regulation p53 but also displayed enhanced 38 
expression of Agt, renin and AT1R. VDR deficient podocytes also displayed an increase 39 
in mRNA expression for p53, Agt, renin, and AT1R. Interestingly, renal tissues of VDR-40 
M as well as VDR heterozygous (h) mice displayed attenuated expression of 41 
deacetylase SIRT1. Renal tissues of VDR-M mice showed acetylation of p53 at lysine 42 
(K) 382 residues inferring that enhanced p53 expression in renal tissues could be the 43 
result of ongoing acetylation, a consequence of SIRT1 deficient state. Notably, 44 
podocytes lacking SIRT1 not only showed acetylation of p53 at lysine (K) 382 residues 45 
but also displayed enhanced p53 expression. Since renal tissues of VDR-M mice also 46 
showed enhanced expression of PPAR-y, it is plausible that either the deficit of SIRT1 47 
has de-repressed expression of PPAR-y or enhanced podocyte expression of PPAR-y 48 
(in the absence of VDR) has contributed to the down regulation of SIRT1.  Based on our 49 
experimental data, we conclude that VDR deficit activates the RAS via SIRT1 50 
modulation.  51 
   52 
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 53 
Vitamin D has been demonstrated to be a negative regulator of renin (20). Interestingly, 54 
VDR knockout mice have also been demonstrated to activate Renin Angiotensin 55 
System (RAS) without displaying a vitamin D deficient state (20). These mice developed 56 
hypertension and cardiac hypertrophy as a consequence to the activation of the RAS 57 
(31). However, levels of angiotensinogen (Agt) and AT1R mRNA were not altered in 58 
cardiac myocytes. Contrary to these findings, renal tissues of VDR knockout diabetic 59 
mice displayed enhanced renin and Agt expression (34). We hypothesized that lack of 60 
VDR would modulate the transcription of the Agt and AT1R in kidney cells of VDR 61 
knockout mice. Further, these effects of VDR deficit status could be mediated through 62 
attenuated Human Silent Information Regulator Type (SIRT) 1 resulting into enhanced 63 
p53 expression by kidney cells. 64 
 SIRT1 is a NAD+-dependent deacetylase that regulates cell phenotype including 65 
cell death/survival, senescence, and metabolism (3). It is involved in transcriptional 66 
silencing of genes by chromatin modification via histone deacetylation, DNA damage 67 
response, and life span extension secondary to calorie restriction (5, 15, 30). SIRT1 is 68 
also a repressor of nuclear receptors such as PPARy by docking with co-repressors - 69 
nuclear receptor corepressor (NCor1) and silencing mediator for retinoid or thyroid-70 
hormone receptors (SMRT, NCor2) (21). Interestingly, SIRT1 negatively regulates p53 71 
expression by deacetylating p53 in response to DNA damage (2, 27, 29). Conversely, 72 
elevation of cellular p53 expression enhances expression of SIRT1 as a negative 73 
feedback.  74 
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Recently, liganded VDR has been shown to modulate expression of FOXO3a 75 
target genes through deacetylation of FOXO3A via SIRT1 in SCC25 cells (4). In these 76 
studies, lack of VDR as well as SIRT1 was associated with phosphorylation of FOXO3a.  77 
In the present study, we have evaluated the effect of VDR down regulation on podocyte 78 
SIRT1 expression and associated up regulation of p53 expression. 79 
We and other investigators previously reported the role of p53 in the transcription 80 
of angiotensinogen and AT1 receptors in cardiac myocytes in high glucose milieu (18). 81 
These effects of p53 were associated with the activation of renin angiotensin system 82 
and cardiac myocyte hypertrophy (18). However, in these studies the role of VDR and 83 
SIRT1 was not explored.  We have recently reported that high glucose down regulated 84 
podocyte VDR expression both in vitro and in vivo studies (24). In these studies, high 85 
glucose-induced down regulation of VDR was associated with the activation of the RAS. 86 
However, we did not explore the role of SIRT1 and p53 in the induction of activation of 87 
the RAS in podocytes. 88 
In the present study, we evaluated the effect of lack of VDR from the genome of 89 
kidney cells on SIRT1 expression both in vivo and in vitro studies. We delineated the 90 
involved molecular mechanisms of the activation of renin angiotensin system in 91 
podocytes lacking VDR.  92 
 93 
  94 
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Material and Methods 95 
VDR Mutant mice 96 
VDR tm1MBD+/- were purchased from Jackson Laboratories (Bar Harbor, Maine), and bred 97 
to develop homozygous VDR mutant (VDR-M, VDR tm1MBD+/+) mice) on FVB/N 98 
background.  99 
Human podocytes 100 
Human podocytes (HPs) were obtained from Dr. Moin A. Saleem (Children’s 101 
renal unit and academic renal unit, University of Bristol, Southmead Hospital, Bristol, 102 
UK). Human podocytes were conditionally immortalized by introducing temperature-103 
sensitive SV40- T antigen by transfection. The cells have additionally been transfected 104 
with a human telomerase construct. These cells proliferate at permissive temperature 105 
(33˚C, conditionally immortalized human podocytes) and enter growth arrest 106 
(conditionally immortalized differentiated human podocytes) after transfer to the non-107 
permissive temperature (37˚C). The growth medium contains RPMI 1640 supplemented 108 
with 10% fetal bovine serum (FBS), 1x Pen-Strep, 1 mM L-glutamine and 1x ITS 109 
(Invitrogen) to promote expression of T antigen. Since incubation media being deficient 110 
(contained only 10% serum) in vitamin D, majority of podocyte VDR was unliganded. 111 
 Silencing for VDR and SIRT1 112 
HPs were transfected with 25 nM VDR siRNA, control-siRNA (Santa Cruz 113 
Biotechnology, Santa Cruz, CA), or SIRT1 siRNA (Cell Signaling) with Siport Neofax 114 
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transfection reagent and left in optiMEM media for 48 hrs. Control and transfected cells 115 
were used under control and experimental conditions.  116 
Western blotting studies 117 
Protein blots of control and experimental cells/renal tissues were processed as 118 
described previously (9). Nitrocellulose membranes were then processed further for 119 
immunostaining with primary antibodies against SIRT1 (anti-rabbit, Santa Cruz 120 
Biotechnology, Santa Cruz, CA), p53 (antimouse, Abcam, Cambridge, San Francisco, 121 
CA), Ack382-p53 (anti-rabbit, Abcam), angiotensinogen (anti-rabbit, Abcam), AT1R (anti-122 
rabbit, Santa Cruz), renin (Santa Cruz), or PPAR-y (anti-rabbit, Cell Signaling, Danvers, 123 
MA) and subsequently with horseradish peroxidase (HRP) labeled appropriate 124 
secondary antibodies. The blots were developed using a chemiluminescence detection 125 
kit (PIERCE, Rockford, IL) and exposed to X-ray film (Eastman Kodak Co., Rochester, 126 
NY). Equal protein loading and the protein transfer were confirmed by immunoblotting 127 
for determination of actin protein using a polyclonal α-Actin antibody (I-19, Santa Cruz, 128 
CA) on the same (stripped) Western blots.  129 
Reverse Transcription PCR Analysis 130 
Control  and experimental  podocytes were used to quantify mRNA expression of VDR, 131 
p53, renin, Agt, AT1R, and SIRT1 as described previously (15).Quantitative PCR was 132 
carried out in an ABI Prism 7900HT sequence detection system using the primer 133 
sequences  as shown below: 134 
VDR (Human)  135 
5 : GACTTTGACCGGAACGTGCCC -3 136 
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5: CATCATGCCGATGTCCACACA -3 137 
Agt (Human)  138 
F: 5-CTGCAAGGATCTTATGACCTGC-3             139 
R: 5-TACACAGCAAACAGGAATGGGC-3 140 
Renin (Human)  141 
 F: 5-AAATGAAGGGGGTGTCTGTGG-3                            142 
R: 5-AAGCCAATGCGGTTGTTAACGC-3 143 
SIRT1 (Human) 144 
F:5’-CAGGTTGCGGGAATCCAAAG-3’ 145 
R:5’-GCTGGGCACCTAGGACATCG-3’ 146 
SYBR green was used as the detector and ROX as a stabilizing dye.  Results (means ± 147 
S.D.) represent number of samples as described in the legend. The data was analyzed 148 
using the Comparative CT method (∆∆CT method). Differences in CT are used to quantify 149 
relative amount of PCR target contained within each well. The data was expressed as 150 
relative mRNA expression with reference to control, normalized to quantity RNA input 151 
by performing measurements on an endogenous reference gene, GAPDH.   152 
Statistical analysis 153 
For comparison of mean values between two groups, the unpaired t test was 154 
used. To compare values between multiple groups, analysis of variance (ANOVA) was 155 
applied and a Bonferroni multiple range test was used to calculate a P-value. Statistical 156 
significance was defined as P<0.05. All values are displayed as mean ± SD.  157 
  158 
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Results 159 
Renal tissues lacking VDR display enhanced expression of p53 and activation of 160 
renin angiotensin system 161 
Since p53 is known to enhance cardiac myocyte expression of angiotensinogen and 162 
AT1R expression (18) we asked whether renal tissues of VDR-M would display 163 
enhanced expression of p53 and associated downstream signaling. Protein blots of 164 
renal tissues of control and VDR mutant mice were probed for p53, angiotensinogen 165 
(Agt), renin, and AT1R and reprobed for actin (n=4). Representative gels in duplicate 166 
are displayed in Fig 1A. Cumulative densitometric data (n=4) are shown as bar graphs. 167 
VDR lacking renal tissues displayed 8 fold increases in p53 expression when compared 168 
to control mice (Fig. 1B). Renal tissues from VDR mutant mice displayed 3 fold increase 169 
in Agt expression (Fig. 1C), 2 fold increase in renin expression (Fig. 1D), and 5-fold 170 
increase in AT1R expression (Fig. 1E). These findings indicate that lack of VDR in these 171 
mice is associated with an upregulation of renal tissue p53 expression leading to the 172 
activation of renin angiotensin system.  173 
VDR deficient podocytes display enhanced expression of p53 and activation of 174 
renin angiotensin system 175 
To confirm the effect of the lack of VDR on podocyte p53 expression and associated 176 
activation of the RAS, podocytes were partially silenced for VDR.  Podocytes were 177 
either silenced for VDR by transfecting them with siRNA-VDR or control (scrambled)-178 
siRNA. Protein blots of SiCon/HPs or SiVDR/HPs (n=4) were probed for p53 and then 179 
reprobed for Agt, renin, and actin. Representative gels (in duplicates) are shown in Fig. 180 
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2A. Cumulative densitometric data are shown as bar graphs. siRNA/HPs displayed 181 
down regulation of VDR expression by 50% when compared to siCon/HPs (Fig. 2B). 182 
VDR deficient podocytes showed 1.8 fold increase in their p53 expression (Fig, 2C) and 183 
similar increase in Agt (Fig. 2D) and renin (Fig 2E) expressions.  184 
To determine the effect of podocyte VDR silencing on the transcription of VDR, p53, 185 
and molecules involved in the RAS, podocytes were transfected with either scrambled 186 
SiRNA (SiCon) or SiRNA-VDR (SiVDR). cDNAs from siCon and SiVDR were amplified 187 
with specific primers for VDR, p53, Agt and renin. Transfection of HPs with SiVDR 188 
decreased VDR expression in podocytes by 50% (Fig. 3A). This decrease in podocyte 189 
VDR transcription was associated with increased p53 transcription only by 25% (data 190 
not shown). Nonetheless there was a significant increase in p53 protein expression (Fig. 191 
2C) in podocyte lacking VDR. Increased functionality of p53 in podocytes silenced for 192 
VDR was further confirmed by display of enhanced transrcription of both Agt (Fig. 3B) 193 
and renin (Fig. 3C) by approximately two fold.  194 
Lack of VDR is associated with down regulation of SIRT1 in VDR-M mice 195 
 SIRT1 is a deacetylase and modulates p53 expression through deacetylation (3, 5). On 196 
that account, lack of SIRT1 has been reported to enhance p53 expression (29). We 197 
asked whether lack of VDR is associated with down regulation of SIRT1. Protein blots of 198 
renal tissues (n=4) of control and VDR-M mice were probed for SIRT1 and the same 199 
blots were reprobed for GAPDH. Representative gels are displayed in Fig. 4A. Renal 200 
tissues of VDR-M mice displayed attenuated expression of SIRT1. Since renal tissues 201 
of VDR-M mice barely displayed any expression of SIRT1, we also evaluated renal 202 
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tissue SIRT1 expression in VDR-heterozygous mice (h). Protein blots of renal tissues of 203 
control (n=4) and VDR-H (n=5) were probed for SIRT1 and reprobed for GAPDH. Gels 204 
are displayed in Fig. 4B. Densitoemetric data are shown as bar graphs in Fig. 4C. Renal 205 
tissues of VDR-h mice displayed attenuated expression of SIRT1. 206 
 p53 acetylation at lysine (K) 382 residues is prevailed in renal tissues lacking 207 
VDR 208 
Since acetylation of p53 at k382 residues has been shown to be associated with 209 
enhanced p53 expression, we expected lack of VDR in renal tissues would also be 210 
associated with acetylation p53 at K382 residues. Renal tissues of control (n=3) and 211 
VDR-M (n=3) were probed for SIRT1. The same blots were stripped and reprobed for 212 
p53, Ack382-p53, Agt, AT1R, PPAR-y, and GAPDH. Gels are displayed in Fig. 5. Renal 213 
tissues of VDR-M mice displayed attenuated expression of SIRT1 but enhanced 214 
expression of p53 and acetylation at the 382 residue site. These findings indicate that 215 
down regulation of SIRT1 in mice lacking VDR may be enhancing p53 expression 216 
through acetylation at K382 residues. Renal tissues of VDR-M mice also displayed 217 
enhanced expression of Agt and AT1R. Interestingly, renal tissues of VDR-M mice 218 
displayed enhanced expression of PPAR-y. Since SIRT1 is a component of PARP-y 219 
repressor complex, lack of SIRT1 is likely to disrupt repressor complex (21). 220 
Podocytes partially lacking SIRT1 from their genome display enhanced 221 
acetylation of p53 at K382 residues in podocytes 222 
Since SIRT1 is a deacetylase, we asked whether partial deficit of SIRT1 from the 223 
genome of podocytes would enhance acetylation of p53 at K382 residues. Human 224 
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podocytes were transfected either control (C )- siRNA or SIRT1-siRNA. Control cells, C-225 
siRNA- and SIRT1-siRNA transfected cells were incubated in media for 24 hours and 226 
extracted for protein and RNA.  227 
 cDNAs were prepared and amplified with a probe specific for SIRT1. Results are 228 
displayed in Fig. 6A. Podocytes transfected with SIRT1-siRNA displayed 50% down 229 
regulation of SIRT1 mRNA expression. 230 
Protein blots were probed for SIRT1, p53, ac-k382p53, and GAPDH. Gels are 231 
displayed in Fig. 6B. Podocytes- transfected with SIRT1-siRNA displayed modest down 232 
regulation (30% only) of SIRT1 protein expression. Nonetheless, podocytes transfected 233 
with SIRT1-siRNA displayed both robust acetylation of p53 at K382 residues and an 234 
increased p53 protein expression. Thus, it appears that despite 50% down regulation of 235 
SIRT1 gene expression in the genome of podocytes, protein expression of SIRT1 in 236 
SIRT1-siRNA transfected podocytes was not reduced to the same magnitude.  We 237 
would like to clarify this discrepancy in mRNA and protein expression of SIRT1 in these 238 
studies. Downstream signaling in the form of robust increase in p53 acetylation at K382 239 
residues as well as abundant p53 protein expression confirmed the deficit in 240 
functionality of SIRT1 in these podocytes. We speculate that sustained increase in 241 
podocyte expression of p53 stimulated SIRT1 expression in podocytes partially lacking 242 
SIRT1 from their genome as a negative feedback. Moreover, these findings are 243 
consistent with the observations of other investigators (5, 15).  244 
High Glucose milieu down regulates SIRT1, enhances p53 acetylation and RAS 245 
activation 246 
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We and other investigators have previously reported down regulation of podocyte 247 
VDR expression in adverse milieus both in vitro and in vivo studies (8, 9, 25, 26, 34). 248 
We asked whether high glucose milieu would also down regulate SIRT1 and enhance 249 
podocyte p53 expression and associated downstream signals. Human podocytes were 250 
incubated in media containing either normal glucose (5 mM, control) or high glucose (35 251 
mM) for 24 and 48 hours. Protein blots were probed for SIRT1. The same blots were 252 
reprobed for p53, Agt, and GAPDH. Gels are displayed in Fig. 7A. High glucose 253 
attenuated podocyte SIRT1 expression but enhanced expression of both p53 and Agt at 254 
24 hours. However, after 48 hours SIRT1 expression is also up regulated when 255 
compared to 24 hours treatment. However, these findings are consistent with the other 256 
investigators indicating that in due course of time elevated levels of p53 would also 257 
enhance SIRT1 expression as a negative feedback (as mentioned above, Fig. 6B; 5, 6). 258 
Therefore, acetylation of p53 and its expression is the determinant of functionality of the 259 
SIRT1.  260 
To determine the time course effect of high glucose on podocyte SIRT1 and p53 261 
expression, human podocytes (HPs)  were incubated in media containing either normal 262 
glucose (5 mM) or high glucose (35 mM) for  variable time periods (4, 12, 24, and 48 263 
hours). Protein blots were probed for SIRT1. The same blots were reprobed for p53 and 264 
GAPDH. Gels are displayed in Fig. 7B. High glucose down regulated SIRT1 expression 265 
up to 24 hours. However, it is normalized to some extent as a negative feedback at 48 266 
hours. Conversely, p53 expression was upregulated up to 24 hours and then declined at 267 
48 hours. These findings further support the involved dynamics in SIRT1 and p53 268 
expression, which are consistent both under physiological and pathological states. 269 
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 270 
Enhanced  podocyte VDR expression is associated with increased SIRT1 271 
expression  272 
Since down regulation of VDR modulated podocyte SIRT1 expression, we expected 273 
enhanced podocyte VDR expression would be associated with enhanced SIRT1 274 
expression. To determine the effect of enhanced podocyte VDR expression on SIRT1 275 
expression, podocytes were transfected with control plasmid (pcDNA), SIRT1, or VDR. 276 
In parallel sets of experiments podocytes were incubated in media containing VDR 277 
agonist (VDA, EB1089, 1 nM) for 24 hours.  Protein blots were probed for SIRT1 and 278 
reprobed for GAPDH.  Gels are displayed in Fig.  8A. Podocytes transfected with VDR 279 
or treated with VDA displayed enhanced expression of SIRT1. 280 
To determine the time course effect of VDA on podocyte SIRT1 expression, podocytes 281 
were incubated in media containing VDA (EB1089, 1 nM) for variable time periods (0, 282 
2,4, 8, 12, 24 hours). Protein blots were probed for SIRT1 and reprobed for GAPDH. 283 
VDA enhanced SIRT1 expression as early as 2 hours (Fig. 8B). 284 
Proposed scheme depicting the role of VDR in the activation of the RAS is shown in Fig. 285 
9. Lack of VDR in podocytes induces down regulation of SIRT1, which enhances 286 
podocyte p53 expression through allowing acetylation of p53. Enhanced p53 expression 287 
induces transcription of Agt and AT1R leading to the activation of the RAS. 288 
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Discussion 289 
VDR knockout mice have been demonstrated to activate RAS as well as its 290 
downstream effects in the form of cardiac hypertrophy (31). It was suggested that the 291 
activation of the RAS was a consequence of disruption of vitamin D and VDR nexus 292 
(20). In the present study, we determined that lack of VDR was associated with 293 
enhanced expression of angiotensinogen and AT1 by renal tissues as well as by 294 
podoctyes. This effect of VDR deficit seems to be mediated by enhanced expression of 295 
p53 both in renal tissues and podocytes. Occurrence of acetylation of p53 at K382 296 
residues contributed to enhanced expression of p53 in renal tissues lacking SIRT1.  297 
Recently, high Ang II states including high glucose and HIV milieus have been 298 
reported to cause down regulation of VDR in podocytes (8, 9, 25, 26, 34).High Ang II 299 
states down regulate podocyte VDR by multiple mechanisms including enhanced VDR 300 
degradation via proteasomal pathway and through transcription of CYP24A via de-301 
repression of co-repressor complexes at CYP24A1 promoter (26). Since CYP24A1 302 
metabolizes vitamin D, enhanced podocyte CYP24A1 state would be associated with 303 
low vitamin D which would lead to the accelerated degradation of VDR. Additionally, 304 
Ang II as well as conditions associated with high Ang II states such as high glucose and 305 
HIV milieus are associated with  enhanced podocyte expression of SNAIL (19, 32); the 306 
latter is a repressor of transcription of VDR (17, 32). Knocking of VDR in kidney cells 307 
has been demonstrated to enhance the activation of renin angiotensin system (RAS) 308 
(8,9,25, 26, 34). Thus, it appears that Ang II perpetuates its production through down 309 
regulation of VDR in kidney cells.  310 
 311 
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We have previously reported that high glucose enhanced kidney cell p53 and 312 
angiotensinogen expression in podocytes (28). We and other investigators also 313 
demonstrated similar phenomenon in cardiac myocytes (18). In the present study, we 314 
asked whether high glucose induced activation of the RAS is mediated through down 315 
regulation of SIRT1 and upregulation of p53. SIRT1 is a negative regulator of p53 316 
because of its deacetylase activity (3); conversely, p53 enhances SIRT1 expression as 317 
a negative feedback (5, 15). Because of this complex inter-relationship between these 318 
molecules, downstream functionality in the form of p53 acetylation  or p53 expression 319 
seems to be a better marker of SIRT1 activity rather than to mere SIRT1 protein 320 
expression. In the present study too, podocytes partially silenced for SIRT1 displayed 321 
robust acetylation of p53 and abundant expression p53 and thus confirming a deficit in 322 
functionality of SIRT1. Since p53 was in abundance it is likely to increase expression of 323 
SIRT1 in these cells, as negative feedback. As expected, despite lack of SIRT1 in the 324 
genome of these podocytes, these cells displayed moderate SIRT1 expression. This 325 
aspect was better exemplified in time course effect of high glucose on podocyte SIRT1 326 
expression. High glucose attenuated podocyte SIRT1 expression but enhanced p53 327 
expression during early time period (up to 24 hours); however, at 48 hours, podocyte 328 
SIRT1 expression was up regulated  and p53 expression diminished partially. These 329 
findings highlight ongoing dynamic relationship between these molecules during 330 
sustained exposure of adverse milieus.  331 
SIRT1 protein directly interacts with PPARγ to form a complex and may thus 332 
control acetylation and deacetylation status of PPARγ (13, 23). PPARγ also binds to the 333 
promoter of SIRT1 gene and control the expression SIRT1 gene (23). Thus, both 334 
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PPARγ and SIRT1 inversely regulate each other’s expression. The involved mechanism 335 
of SIRT1 down regulation in cells lacking VDR is very well understood to date. Both 336 
VDR and PPARγ compete for binding with RXR for their functionality (1). Therefore, 337 
PPAR-γ binding with RXR will go unchallenged in cells lacking VDR. Since PPARγ 338 
negatively regulates SIRT1 expression, it would down regulate SIR1 expression in 339 
conditioned cells lacking VDR.  Additionally, SIRT1 is also a part of PPAR-y-RXR 340 
repressor complex docking on DNA binding site of PPRE (21); therefore, lack of SIRT1 341 
would disrupt the repressor complex and de-repress the target gene expression such as  342 
PPAR-y. In the present study, renal tissues lacking VDR displayed enhanced 343 
expression of PPARy and attenuated expression of SIRT1. We speculate that either 344 
PPARy would be contributing to down regulation of SIRT1 expression in podocytes 345 
lacking VDR or lack of SIRT1 de-repressing the expression of PPARy. It would be worth 346 
while exploring this aspect of the investigation in our future studies.  347 
p53 is normally maintained at a low concentration in quiescent cells by 348 
continuous ubiquitination and proteasome-mediated degradation (6). However, p53 349 
expression gets up regulated in cells under stress because of suppression of p53 350 
ubiquitination and enhancement of p53 acetylation. Under stress, SIRT1, a deacetylator 351 
of p53 is destabilized and degraded via proteasomal pathway (7). Reduction of 352 
deacetylation of p53 leads to the acetylation of p53 (33). On the other hand, up 353 
regulation of SIRT1 inactivates p53 (3, 5). In the present study, renal tissues of VDR 354 
mutant mice as well as VDR-silenced podocytes displayed enhanced expression of 355 
podocyte p53. Since lack of VDR in renal tissues was not only associated with down 356 
regulation of SIRT1 but was also associated with acetylation of p53 at 382 residues of 357 
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renal tissues, it is likely upregulation of p53 expression was contributed by lack of 358 
SIRT1 to some extent. 359 
Deficiency of vitamin D has been incriminated a variety of chronic diseases 360 
including tuberculosis (16), HIV (10), hypertension (12), colon cancer (11) and chronic 361 
kidney diseases (22). However, outcome of clinical trials of vitamin D therapy in clinical 362 
trials of disease has not shown very promising data (14). Since vitamin D worked 363 
through VDR, functionality of vitamin D could be better be monitored by VDR status. It 364 
has been shown in patients of colon cancer that vitamin D receptor could not be 365 
optimally raised with vitamin D therapy in several instances and these patients did not 366 
respond to vitamin D therapy (17). We have recently reported that HIV down regulated 367 
podocyte VDR expression thorough CpG methylation at VDR promoter (8). In these 368 
studies, Vitamin D could not up regulate podocyte VDR expression optimally; however, 369 
use of a demethylating agent in combination with vitamin D could optimally increase 370 
podocyte VDR expression in HIV milieu (8). We propose that discrepancy in vitamin D 371 
clinical trials may be related to the inability of vitamin D in upregulating VDR optimally 372 
because of the down regulation as a consequence of epigenetics. It will be worth 373 
investing this aspect of investigation in future studies. 374 
Vitamin D has been reported to be a negative endocrine regulator of renin 375 
transcription (20). This effect of vitamin D has been attributed to liganded-VDR which 376 
blocks the binding of CRP binding protein (CBP) at renin promoter and thus preventing 377 
the transcription of renin. On that account, vitamin D is being used to down regulate 378 
renin angiotensin system in patients of chronic kidney diseases (22). In the present 379 
study, we observed that lack of unliganded- VDR enhances transcription of several 380 
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molecules involved in the activation of the RAS. During vitamin D deficient state, there 381 
is a reduction of total VDR because of decreased transcription of VDR and enhanced 382 
degradation of unliganded VDR (See Scheme in Fig. 10).  Thus, vitamin D deficient 383 
status is associated with a decrease in both unliganded (UL) and liganded (L) VDR. In 384 
this scenario, lack of liganded VDR would sustain the transcription of renin, whereas, 385 
lack of unliganded VDR would enhance transcription of angiotensinogen and AT1R via 386 
modulation of p53 expression.  Theoretically, unliganded VDR-induced AT1R activation 387 
should down regulate renin gene expression; however, this negative feedback effect of 388 
AT1R activation is likely be nullified or neutralized because of deficient liganded VDR 389 
mediated-enhanced renin transcription. Thus, it appears that lack of VDR or VDR 390 
deficient state has multiple ways to activate the RAS.  391 
In conclusion, we report for the first time that lack of VDR in the genome kidney 392 
cells enhances expression of p53 via down regulation of SIRT1 resulting into enhanced 393 
transcription of Agt and AT1R that further leads to the activation of the RAS.  394 
  395 
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Figure legend 515 
Fig. 1 Renal tissues lacking VDR display enhanced expression of p53 and 516 
activation or renin angiotensin system 517 
A. Protein blots of renal tissues of control (FVB/N) and VDR mutant  (M) mice were 518 
probed for p53, angiotensinogen (Agt), renin, and AT1R and reprobed for actin (n=4).  519 
 Representative gels in duplicate are displayed.  520 
B. Cumulative densitometric data (n=4) of protein blots probed for p53 and actin in the 521 
form of bar graphs.  522 
C. Mean Agt/Actin ratio of renal tissue protein blots from control and VDR-M mice (n=4). 523 
D. Mean Renin/Actin ration of renal tissue protein blots from control VDR mutant mice 524 
(n=4) 525 
E. Mean AT1R/Actin ratio of renal tissues from control and VDR-M mice (n=4).  526 
*P<0.05 compared to respective FVB/N 527 
Fig. 2. VDR deficient podocytes display enhanced expression of p53 and 528 
activation of renin angiotensin system 529 
Podocytes were either silenced for VDR by transfecting them with siRNA-VDR (Si/VDR) 530 
or control (scrambled)-siRNA (SiCon). Protein blots of Si-Con or SiVDR (n=4) were 531 
probed for p53 and then reprobed for Agt, renin, and actin.  532 
A. Representative gels (in duplicates) are shown.  533 
B. Cumulative densitometric data (VDR/Actin ratios) are shown as bar graphs (n=4).  534 
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C. Mean p53/actin ratios from SiVDR and SiCon protein blots are shown as bar 535 
graphs (n=4). 536 
D. Mean Agt/Actin ratios from SiVDR and SiCon protein blots are shown as bar 537 
graphs (n=4). 538 
E. Mean Renin/Actin ratios SiVDR and SiCon protein blots are shown as bar graphs 539 
(n=4). 540 
*P<0.05 compared with respective SiCon. 541 
Fig. 3. Effect of VDR silencing on podocyte Agt and renin mRNA expression 542 
Podocytes were transfected with either scrambled siRNA (SiCon) or siRNA-VDR 543 
(SiVDR) (n=4). cDNAs from SiCon and SiVDR were amplified with specific 544 
primers for VDR,  Agt, and renin.  545 
A. VDR mRNA expression by SiCon and SiVDR is displayed as bar graphs.  546 
B. Agt mRNA expression by SiCon and SiVDR is displayed as bar graphs.  547 
C. Renin mRNA expression by SiCon and SiVDR. is displayed as bar graphs. 548 
*P<0.05 vs. SiCon 549 
Fig. 4. Lack of VDR is associated with down regulation of SIRT1 in VDR-M mice 550 
A. Protein blots of renal tissues (n=4) of control and VDR-M mice were probed for 551 
SIRT1 and the same blots were reprobed for GAPDH. Representative gels in duplicate 552 
are shown.  553 
B. Protein blots of renal tissues of control (n=4) and VDR-heterozygous (h) (n=5) were 554 
probed for SIRT1 and reprobed for GAPDH. Gels are displayed.  555 
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C. Densitoemetric data (SIRT1/GAPDH) of protein blots of Fig. B are shown as bar 556 
graph. 557 
*P<0.05 compared with FVB/N 558 
Fig. 5. Lack of SIRT1 is associated with p53 acetylation at K382 residues in renal 559 
tissues of VDR-M mice 560 
A. Renal tissues of control (n=3) and VDR-M (n=3) were probed for SIRT1. The same 561 
blots were stripped and reprobed for p53, Ack382-p53, Agt, AT1R, PPAR-y, and GAPDH. 562 
Gels are displayed.  563 
B. Cumulative densitometric data (variable/GAPDH ratio) are shown. 564 
*P<0.05 compared with respective FVB/N 565 
Fig. 6.  Podocytes partially lacking SIRT1 from their genome display enhanced 566 
acetylation of p53 at K382 residues in podocytes 567 
A. Human podocytes were transfected either control (C )- siRNA or SIRT1-siRNA. 568 
Control cells, C-siRNA- and SIRT1-siRNA transfected cells were incubated in 569 
media for 24 hours. Total RNA as well as proteins was harvested. cDNAs were 570 
prepared and amplified with a probe specific for SIRT1. Results are displayed as 571 
bar graph. 572 
B. Protein blots of control (C )- siRNA or SIRT1-siRNA. Control cells, C-siRNA- and 573 
SIRT1-siRNA transfected cells were probed for SIRT1, p53, ac-K382p53, and 574 
GAPDH. Gels are displayed.   575 
Fig. 7. High glucose down regulates SIRT1 in a time dependent manner 576 
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A. Human podocytes were incubated in media containing either normal glucose 577 
(5 mM, control) or high glucose (35 mM) for 24 and 48 hours. Protein blots 578 
were probed for SIRT1. The same blots were reprobed for p53, Agt, and 579 
GAPDH. Gels are displayed.   580 
B. Human podocytes  were incubated in media containing either normal glucose 581 
(5 mM) or high glucose (35 mM) for  variable time periods (4, 12, 24, and 48 582 
hours). Protein blots were probed for SIRT1. The same blots were reprobed 583 
for p53 and GAPDH. Gels are displayed. 584 
Fig. 8. Enhanced  podocyte VDR expression is associated with increased SIRT1 585 
expression  586 
A. Podocytes were transfected with either control plasmid (pcDNA), SIRT1, or VDR. In 587 
parallel sets of experiments podocytes were incubated in media containing VDR agonist 588 
(VDA, EB1089, 1 nM) for 24 hours.  Protein blots were probed for SIRT and reprobed 589 
for GAPDH.  Gels are displayed.  590 
B. Podocytes were incubated in media containing VDA (EB1089, 1 nM) for variable time 591 
periods (0, 2, 4, 8, 12, 24 hours). Protein blots were probed for SIRT1 and reprobed for 592 
GAPDH. Gels are displayed. 593 
Fig. 9. Proposed scheme  594 
Lack of VDR in podocytes induces down regulation of SIRT1, which enhances podocyte 595 
p53 expression through allowing acetylation of p53. Enhanced p53 expression induces 596 
transcription of Agt and AT1R leading to the activation of the RAS. 597 
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Fig. 10. Unliganded VDR complements liganded VDR-mediated renin transcription 598 
in vitamin D deficient state 599 
Vitamin D deficient state lacks both liganded and unliganded VDR. Lack of liganded 600 
VDR would enhance the transcription of renin, whereas, lack of unliganded VDR would 601 
stimulate the transcription of angiotensinogen and AT1R. Unliganded VDR-induced 602 
AT1R activation should down regulate renin gene expression; however, this negative 603 
feedback effect of AT1R activation would be neutralized because of deficient liganded 604 
VDR-stimulated renin transcription.  605 
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